Palovarotene for Fibrodysplasia Ossificans Progressiva (FOP): Results of a Randomized, Placebo-Controlled, Double-Blind Phase 2 Trial.

( 18 ) Assuming that a higher dose results in increased efficacy, the power to detect a significant trend over the dose range (Cochran‐Armitage test of trend; α = 0.05) was tested in six scenarios, based on hypothesized efficacy, with chosen sample sizes pooled across Cohort 1 and Cohort 2: placebo: n = 10; palovarotene 5/2.5 mg: n = 9; palovarotene 10/5 mg: n = 21 (Table S 5 ).

also in 9,775 other papers